Navigation Links
Step forward in foot-and-mouth disease understanding
Date:12/9/2011

Researchers at the University of Leeds have been studying an enzyme called 3D which plays a vital role in the replication of the virus behind the disease. They have found that this enzyme forms fibrous structures (or fibrils) during the replication process. What's more, they have found a molecule which can prevent these fibrils forming.

The project was funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and its findings have been published by the Journal of Virology.

"It's too much of a jump to say that we've found a potential drug target for treatment of foot-and-mouth disease because there's still such a lot we don't know," says Dr Nicola Stonehouse of the University of Leeds' Faculty of Biological Sciences. "However, we do think these findings are significant and provide us with a new avenue for exploration."

Foot-and-mouth is a one of the most readily transmissible diseases known to man, but the mechanisms by which it infects animals are not well understood. The virus responsible for the disease is able to reproduce very quickly, enabling it to cause widespread devastation in a short space of time. The 2001 outbreak in the UK resulted in the deaths of around seven million sheep and cattle at an extremely high cost to the British agricultural sector. Another, more contained outbreak, occurred in 2007.

In laboratory experiments, the research team were able to see that the 3D enzyme forms fibrils when it is copying genetic information it requires to replicate. The implications of these fibrils are not yet fully understood, but it is thought they may play an important role in the reproduction process. If this is the case, having already found a molecule to block the fibril formation could be significant.

"The next stage of our research will be to investigate these fibrils further, to look at their structure and purpose," says PhD student Kris Holmes, who has been working on the project.

Because FMD is classed as a dangerous pathogen, only one laboratory in the UK the Institute for Animal Health at Pirbright, in Surrey is licensed to work with the actual virus. In this research, the Leeds team used a simple, non-harmful model of the virus.


'/>"/>
Contact: Dr Nicola Stonehouse
n.j.stonehouse@leeds.ac.uk
44-113-343-3102
University of Leeds
Source:Eurekalert

Related biology news :

1. Stampede charges computational science forward in tackling complex societal challenges
2. Big steps forward in human functional brain imaging, but collaborations key to patient benefit
3. Hips take walking in stride; ankles put best foot forward in run
4. ONR, Marine Corps show alternative energy use at forward operating bases can save dollars, lives
5. Stroke research takes 2 steps forward
6. $1.6 million to take forward breakthrough research in heart disease
7. Growing drought-tolerant crops inching forward
8. CAKE offers way forward for climate change adaptation
9. A fat forward research tool
10. Meteosat Third Generation takes a step forward
11. First adhere, then detach and glide forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
Breaking Biology Technology: